Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Am J Med. 2020 Aug 18;134(3):370–373.e1. doi: 10.1016/j.amjmed.2020.06.045

Table 1.

Demographics of the Study Cohort by Appropriateness of Starter Pack Fill*

Total (n = 3711) Appropriate (n = 2941) Inappropriate (n = 770) P Value
Rivaroxaban 3220 (86.8) 2566 (87.2) 654 (84.9) 0.09
Age at fill date, mean (SD) 62.8 (15.1) 62.4 (15.3) 64.7 (14.1) < 0.001
% Female 1871 (50.4) 1469 (49.9) 402 (52.2) 0.27
Race/Ethnicity 0.10
 Asian 51 (1.4) 39 (1.3) 12 (1.6)
 Black 519 (14.0) 426 (14.5) 93 (12.1)
 Hispanic 248 (6.7) 184 (6.3) 64 (8.3)
 White 2471 (66.6) 1966 (66.8) 505 (65.6)
 Unknown 422 (11.4) 326 (11.1) 96 (12.5)
Census Region 0.67
 Midwest 997 (26.9) 803 (27.3) 194 (25.2)
 Northeast 297 (8.0) 234 (8.0) 63 (8.2)
 South 1576 (42.5) 1250 (42.5) 326 (42.3)
 West 834 (22.5) 649 (22.1) 185 (24.0)
 Unknown 7 (0.2) 5 (0.2) 2 (0.3)
*

Data presented is the number (percentage) of patients unless otherwise indicated. Comparison between the 2 groups was performed using χ2 tests and Fisher exact tests for binary variables and Wilcoxon rank-sum tests for continuous variables. SD = standard deviation.